June 11, 2020 / 1:17 PM / a month ago

BRIEF-BridgeBio Pharma's ML Bio Announces Dosing Of First Subject In Phase 1 Trial For Limb Girdle Muscular Dystrophy Type 2I

June 11 (Reuters) - BridgeBio Pharma Inc:

* BRIDGEBIO PHARMA’S ML BIO SOLUTIONS ANNOUNCES DOSING OF FIRST SUBJECT IN PHASE 1 CLINICAL TRIAL OF BBP-418 FOR LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2I (LGMD2I) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below